Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMMB Chemomab Therapeutics	$1.20 +1.7%	$1.28	$0.87 ▼ $2.55	$22.25M	0.48	218,098 shs	86,693 shs
EDSA Edesa Biotech	$2.00	$2.10	$1.55 ▼ $5.59	$14.05M	0.41	489,966 shs	5,400 shs
TCRT Alaunos Therapeutics	$4.91 +9.6%	$2.90	$1.31 ▼ $7.40	$7.35M	-1.08	138,794 shs	32,712 shs
UBX UNITY Biotechnology	$0.80 +6.7%	$0.85	$0.66 ▼ $3.10	$12.91M	1.05	164,027 shs	96,187 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMMB Chemomab Therapeutics	+1.69%	0.00%	-12.09%	+3.45%	+20.14%
EDSA Edesa Biotech	0.00%	-0.50%	+2.04%	-21.26%	-53.60%
TCRT Alaunos Therapeutics	+9.60%	+34.15%	+84.59%	+226.03%	-27.06%
UBX UNITY Biotechnology	+6.67%	+3.09%	+2.70%	-33.33%	-43.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	Company Ownership	Earnings & Valuation
CMMB Chemomab Therapeutics	3.1728 of 5 stars	3.5	5.0	0.0	1.7	0.6
EDSA Edesa Biotech	3.1629 of 5 stars	3.5	5.0	0.0	1.7	0.6
TCRT Alaunos Therapeutics	0.3734 of 5 stars	0.0	5.0	0.0	0.8	0.0
UBX UNITY Biotechnology	3.3936 of 5 stars	3.3	2.0	4.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMMB Chemomab Therapeutics	3.00	Buy	$8.50	608.33% Upside
EDSA Edesa Biotech	3.00	Buy	$21.00	950.00% Upside
TCRT Alaunos Therapeutics	0.00	N/A	N/A	N/A
UBX UNITY Biotechnology	2.50	Moderate Buy	$3.75	368.75% Upside

Current Analyst Ratings Breakdown

Latest TCRT, CMMB, UBX, and EDSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	UBX UNITY Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$4.00 ➝ $2.00
5/16/2025	CMMB Chemomab Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$11.00 ➝ $10.00
5/16/2025	UBX UNITY Biotechnology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$6.00 ➝ $1.00
4/23/2025	UBX UNITY Biotechnology	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/23/2025	UBX UNITY Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
3/25/2025	UBX UNITY Biotechnology	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	$0.61 per share	N/A
TCRT Alaunos Therapeutics	$11K	732.04	N/A	N/A	$1.29 per share	3.81
UBX UNITY Biotechnology	$240K	57.37	N/A	N/A	$0.39 per share	2.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMMB Chemomab Therapeutics	-$13.94M	-$0.76	N/A	N/A	N/A	N/A	-106.70%	-82.18%	8/20/2025 (Estimated)
EDSA Edesa Biotech	-$6.17M	-$1.59	N/A	N/A	N/A	N/A	-187.01%	-78.72%	8/8/2025 (Estimated)
TCRT Alaunos Therapeutics	-$4.68M	N/A	0.00	∞	N/A	N/A	-169.30%	-124.25%	8/13/2025 (Estimated)
UBX UNITY Biotechnology	-$25.99M	-$1.62	N/A	N/A	N/A	N/A	-246.82%	-58.81%	7/22/2025 (Estimated)

Latest TCRT, CMMB, UBX, and EDSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	CMMB Chemomab Therapeutics	-$0.20	-$0.14	+$0.06	-$0.14	N/A	N/A
5/15/2025	Q1 2025	TCRT Alaunos Therapeutics	-$4.50	-$0.67	+$3.83	-$0.67	N/A	$0.00 million
5/14/2025	Q2 2025	EDSA Edesa Biotech	-$0.30	-$0.30	N/A	-$0.30	N/A	N/A
4/22/2025	Q1 2025	UBX UNITY Biotechnology	-$0.43	-$0.43	N/A	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A
UBX UNITY Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMMB Chemomab Therapeutics	N/A	5.33	5.33
EDSA Edesa Biotech	N/A	15.72	15.72
TCRT Alaunos Therapeutics	N/A	1.00	1.00
UBX UNITY Biotechnology	N/A	1.95	1.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMMB Chemomab Therapeutics	46.05%
EDSA Edesa Biotech	5.50%
TCRT Alaunos Therapeutics	27.72%
UBX UNITY Biotechnology	29.49%

Insider Ownership

Company	Insider Ownership
CMMB Chemomab Therapeutics	11.91%
EDSA Edesa Biotech	22.60%
TCRT Alaunos Therapeutics	16.14%
UBX UNITY Biotechnology	5.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMMB Chemomab Therapeutics	20	18.86 million	16.61 million	Not Optionable
EDSA Edesa Biotech	20	7.02 million	5.44 million	Not Optionable
TCRT Alaunos Therapeutics	40	1.64 million	1.38 million	No Data
UBX UNITY Biotechnology	60	17.21 million	16.21 million	Optionable

TCRT, CMMB, UBX, and EDSA Headlines

Recent News About These Companies

UBX Unity Biotechnology, Inc. - Seeking Alpha

June 24 at 8:09 PM | seekingalpha.com

HC Wainwright & Co. Downgrades Unity Biotechnology (UBX)

May 28, 2025 | msn.com

Unity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho Securities

May 18, 2025 | theglobeandmail.com

Bay Area biotech company Unity lays off every single worker, including CEO

May 7, 2025 | msn.com

Bay Area biotech company Unity, once worth $700M, lays off entire remaining workforce

May 5, 2025 | msn.com

South San Francisco biotech company lays off entire workforce, including CEO

May 5, 2025 | msn.com

Unity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 roles

May 5, 2025 | fiercebiotech.com

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

May 1, 2025 | globenewswire.com

NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325

April 25, 2025 | ophthalmologytimes.com

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

April 22, 2025 | globenewswire.com

Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology price target lowered to $4 from $6 at Chardan

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology announces results from ASPIRE Phase 2b study in DME

March 25, 2025 | markets.businessinsider.com

Unity reports topline outcomes from trial of diabetic macular oedema therapy

March 25, 2025 | msn.com

UNITY Biotechnology tanks on mixed results for eye disease drug

March 25, 2025 | thepharmaletter.com

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

March 25, 2025 | zacks.com

UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema

March 24, 2025 | finance.yahoo.com

Unity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edema

March 24, 2025 | ophthalmologytimes.com

UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial

March 24, 2025 | msn.com

Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls

March 24, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, CMMB, UBX, and EDSA Company Descriptions

Chemomab Therapeutics NASDAQ:CMMB

$1.20 +0.02 (+1.69%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$1.20 0.00 (-0.42%)

As of 07:57 AM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Edesa Biotech NASDAQ:EDSA

$2.00 0.00 (0.00%)

Closing price 06/24/2025 03:51 PM Eastern

Extended Trading

$2.06 +0.06 (+2.95%)

As of 07:06 AM Eastern

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Alaunos Therapeutics NASDAQ:TCRT

$4.91 +0.43 (+9.60%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$4.50 -0.42 (-8.45%)

As of 07:38 AM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

UNITY Biotechnology NASDAQ:UBX

$0.80 +0.05 (+6.67%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$0.80 +0.01 (+0.63%)

As of 07:31 AM Eastern

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time